Vertiflex named Michael Enxing the company's new vice president and COO.
Here are five things to know:
1. Mr. Enxing has more than 20 years of experience in the medical device, spinal and chronic pain fields. He was previously the vice president of sales at Nevro Corp., which grew domestically and internationally during his tenure.
2. In his new role, Mr. Enxing will be responsible for leading Vertiflex's sales, marketing, health economics/reimbursement and professional education strategies related to the Superion Indirect Decompression System for lumbar spinal stenosis.
3. Vertiflex's President and CEO Earl R. Fender described Mr. Enxing as a "visionary" and he believes Mr. Enxing will drive team success and improve the customer engagement experience. "We are confident that Michael's track record of significantly scaling businesses, will add considerable value to Vertiflex, our investors, physician providers and most of all patients, who will benefit from Superion's demonstrated and durable clinical and safety profile."
4. The company was founded in 2005 and received FDA clearance for a premarket approval trial in 2015. Mr. Enxing enters the company after it received approval for the PMA and Category I reimbursement for Superion. "Based on my prior experience in commercializing an early generation product for lumbar spinal stenosis, I believe Superion, having significant published peer-reviewed data, is positioned as the best-in-class minimally invasive solution for lumbar spinal stenosis that will also compare well to open surgical decompression in treating patients suffering from LSS."
5. Mr. Enxing also has experience as vice president of sales and marketing for Vertos Medical and held executive positions with Stryker and Cardio Vascular Solutions.
More articles on orthopedic devices:
Zimmer Biomet CEO David Dvorak exits after 10 years
DePuy Synthes releases single use kits for wrist fracture surgery